CN114470101A - Traditional Chinese medicine composition, preparation method thereof and oral agent containing traditional Chinese medicine composition - Google Patents
Traditional Chinese medicine composition, preparation method thereof and oral agent containing traditional Chinese medicine composition Download PDFInfo
- Publication number
- CN114470101A CN114470101A CN202210250536.3A CN202210250536A CN114470101A CN 114470101 A CN114470101 A CN 114470101A CN 202210250536 A CN202210250536 A CN 202210250536A CN 114470101 A CN114470101 A CN 114470101A
- Authority
- CN
- China
- Prior art keywords
- extract
- chinese medicine
- traditional chinese
- medicine composition
- extracting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 121
- 239000003814 drug Substances 0.000 title claims abstract description 97
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 239000003795 chemical substances by application Substances 0.000 title abstract description 3
- 210000002966 serum Anatomy 0.000 claims abstract description 43
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 21
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 21
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 21
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 21
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 21
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 20
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 13
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 13
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 13
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 13
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 13
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 13
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 13
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 13
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 13
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 230000008569 process Effects 0.000 claims abstract description 8
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 2
- 239000000284 extract Substances 0.000 claims description 81
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 239000000243 solution Substances 0.000 claims description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 238000002156 mixing Methods 0.000 claims description 17
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 15
- 239000012153 distilled water Substances 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- 239000002798 polar solvent Substances 0.000 claims description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 10
- 230000002378 acidificating effect Effects 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 210000000582 semen Anatomy 0.000 claims description 9
- 238000000926 separation method Methods 0.000 claims description 9
- 238000005406 washing Methods 0.000 claims description 9
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 8
- 235000020717 hawthorn extract Nutrition 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 239000002244 precipitate Substances 0.000 claims description 8
- 239000000741 silica gel Substances 0.000 claims description 8
- 229910002027 silica gel Inorganic materials 0.000 claims description 8
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 8
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 8
- 238000010828 elution Methods 0.000 claims description 7
- 239000012535 impurity Substances 0.000 claims description 7
- 239000004375 Dextrin Substances 0.000 claims description 6
- 229920001353 Dextrin Polymers 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000002026 chloroform extract Substances 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims description 4
- 238000004440 column chromatography Methods 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 239000003208 petroleum Substances 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 238000000967 suction filtration Methods 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 239000013078 crystal Substances 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 239000000469 ethanolic extract Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- 230000003472 neutralizing effect Effects 0.000 claims description 3
- 238000009736 wetting Methods 0.000 claims description 3
- FYGDTMLNYKFZSV-MRCIVHHJSA-N dextrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](CO)OC(O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-MRCIVHHJSA-N 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 239000000047 product Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 41
- 230000009471 action Effects 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000004044 response Effects 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 19
- 230000036772 blood pressure Effects 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 241001092040 Crataegus Species 0.000 description 11
- 229930013930 alkaloid Natural products 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 10
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 10
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 10
- 208000031226 Hyperlipidaemia Diseases 0.000 description 10
- 239000005642 Oleic acid Substances 0.000 description 10
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 10
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 230000001603 reducing effect Effects 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 150000003797 alkaloid derivatives Chemical class 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 235000013399 edible fruits Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 6
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 6
- 229960002855 simvastatin Drugs 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 102000019280 Pancreatic lipases Human genes 0.000 description 5
- 108050006759 Pancreatic lipases Proteins 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 235000019626 lipase activity Nutrition 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 229940116369 pancreatic lipase Drugs 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- -1 compounds Phenolic glycosides Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 229930182487 phenolic glycoside Natural products 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 2
- 241001074285 Liparis <scorpaeniform fish> Species 0.000 description 2
- INVGWHRKADIJHF-UHFFFAOYSA-N Sanguinarin Chemical compound C1=C2OCOC2=CC2=C3[N+](C)=CC4=C(OCO5)C5=CC=C4C3=CC=C21 INVGWHRKADIJHF-UHFFFAOYSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 2
- 150000004056 anthraquinones Chemical class 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 210000003989 endothelium vascular Anatomy 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 2
- 238000002331 protein detection Methods 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 241000234282 Allium Species 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000031288 Combined hyperlipidaemia Diseases 0.000 description 1
- 235000007106 Crataegus suborbiculata Nutrition 0.000 description 1
- 241000073432 Crataegus suborbiculata Species 0.000 description 1
- FCEXWTOTHXCQCQ-UHFFFAOYSA-N Ethoxydihydrosanguinarine Natural products C12=CC=C3OCOC3=C2C(OCC)N(C)C(C2=C3)=C1C=CC2=CC1=C3OCO1 FCEXWTOTHXCQCQ-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- UGNZSMZSJYOGNX-UHFFFAOYSA-N Isoviocristine Natural products O=C1C=C(C)C(=O)C2=CC3=CC(OC)=CC(O)=C3C(O)=C21 UGNZSMZSJYOGNX-UHFFFAOYSA-N 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- CFLNHFUPWNRWJA-UHFFFAOYSA-N Obtusin Chemical compound O=C1C2=CC(C)=C(O)C(OC)=C2C(=O)C2=C1C=C(OC)C(OC)=C2O CFLNHFUPWNRWJA-UHFFFAOYSA-N 0.000 description 1
- OBBJQZSMXOJMCN-UHFFFAOYSA-N Obtusin Natural products COc1cc2C=CC(=O)Oc2c3OCC(Oc13)C(=C)C OBBJQZSMXOJMCN-UHFFFAOYSA-N 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 244000173853 Sanguisorba officinalis Species 0.000 description 1
- 235000008282 Sanguisorba officinalis Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 240000000038 Ziziphus mauritiana Species 0.000 description 1
- 235000006545 Ziziphus mauritiana Nutrition 0.000 description 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 1
- 235000013202 a hawthorn Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- WLXGUTUUWXVZNM-UHFFFAOYSA-N anthraglycoside A Natural products C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1OC1OC(CO)C(O)C(O)C1O WLXGUTUUWXVZNM-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002036 chloroform fraction Substances 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- BFBPISPWJZMWJN-UHFFFAOYSA-N methyl 2-[(7-hydroxy-3,7-dimethyloctylidene)amino]benzoate Chemical compound COC(=O)C1=CC=CC=C1N=CCC(C)CCCC(C)(C)O BFBPISPWJZMWJN-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000007950 phenolic glycosides Chemical class 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229940084560 sanguinarine Drugs 0.000 description 1
- YZRQUTZNTDAYPJ-UHFFFAOYSA-N sanguinarine pseudobase Natural products C1=C2OCOC2=CC2=C3N(C)C(O)C4=C(OCO5)C5=CC=C4C3=CC=C21 YZRQUTZNTDAYPJ-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition, a preparation method thereof and an oral agent containing the same, wherein the traditional Chinese medicine composition comprises the following raw materials in parts by mass: see serum 1000: 100-2000 parts of cassia seed: 10-1000 parts of hawthorn: 5-500 of medlar; the traditional Chinese medicine composition provided by the invention has the advantages of high purity of effective components, mild action process, quick response and small side effect.
Description
Technical Field
The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition, a preparation method thereof and an oral preparation containing the same.
Background
The medicinal plant belongs to the genus Allium of Orchidaceae, and is a terrestrial herb, also known as "Yanyu", "Heilong", "dwarf fat baby" or "sheep ear garlic", widely distributed in China, Yun, Gui, Chuan, Shuangguang and the like, is a traditional folk medicinal plant in China, is cool in nature and bitter in taste, has the pharmacological activities of blood coagulation, inflammation resistance, bacteriostasis, antioxidation and the like, and can be used for clearing away heat and toxic materials, cooling blood, stopping bleeding and the like.
At present, the research aiming at the serum at home and abroad mainly focuses on the extraction and analysis of chemical components and the pharmacological activity research of the anti-tumor, antibacterial, anti-inflammatory, antioxidant and hemostatic effects of some active components; but the application of the traditional Chinese medicine composition in the clinical treatment of reducing blood pressure and blood fat is not found.
Hypertension is a very common disease nowadays, most of which occurs in middle-aged and elderly people, but many young people suffer from hypertension along with the accelerated pace of life, increased pressure and the like, and hypertension is a common cardiovascular disease in internal medicine, has many causes, and is essentially genetic and environmental.
Hyperlipidemia is generally concentrated in the elderly patients, and the elderly patients with hyperlipidemia higher than the normal specified range are easy to develop the diseases, wherein the hyperlipidemia comprises hypercholesterolemia, hypertriglyceridemia and combined hyperlipidemia; after the human body forms atherosclerosis due to long-term hyperlipidemia, the blood flow of coronary artery is reduced, the blood vessel cavity is narrowed, the blood injection amount of myocardium is reduced, myocardial ischemia is caused, angina pectoris is caused, and the coronary heart disease is formed; the liver function is damaged due to hyperlipidemia, fatty liver is caused by long-term hyperlipidemia, hepatic atherosclerosis is damaged, and hepatic lobules are also damaged, so that the structure is changed, and the liver function is damaged; hyperlipidemia is easy to form vascular sclerosis, a large amount of lipid substance protein is deposited in plasma after atherosclerosis is formed, the blood flow speed is reduced, rancidity is caused after oxidation, the lipid substance protein is deposited on arterial vascular endothelium, and the arterial vascular endothelium can be damaged after long-term adhesion to the vascular wall, so that vascular sclerosis is caused.
The existing main treatment methods for hypertension and hyperlipidemia comprise methods such as exercise treatment, diet treatment, traditional Chinese medicine conditioning and drug treatment, but the exercise treatment, the diet treatment and the traditional Chinese medicine conditioning are slow in effect and cannot achieve ideal effects due to the restriction of many factors, and western medicines have obvious blood pressure reducing effects but mostly have certain side effects and have certain damage to organs such as heart, kidney and the like.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition and an oral preparation containing the same, which can effectively reduce blood pressure and blood fat of a human body, and have mild action process and small side effect.
The invention also aims to provide a preparation method of the traditional Chinese medicine composition, which can effectively extract the total alkaloid of the effective components in the serum, the anthraquinone components in the cassia seed and the whole components of the hawthorn and the medlar, reduce ineffective components and irritant components, make the action process of the traditional Chinese medicine composition milder, reduce side effects and improve the effects of reducing blood pressure and blood fat.
The technical scheme adopted by the invention is that the preparation method of the traditional Chinese medicine composition specifically comprises the following steps:
and 3, respectively extracting the cassia seed extract, the hawthorn extract and the medlar extract, and mixing the serum extract and the extracts to obtain the traditional Chinese medicine composition.
Further, the specific process of repeatedly extracting in step 1 is as follows:
extracting for 1-10 h at 25-90 ℃ by using an acidic polar solvent, and extracting for 0.5-1.5 h at 25-90 ℃ by using an acidic polar solvent, wherein the pH value of the acidic polar solvent is 1.0-3.0.
Further, the separation and purification process in the step 2 is as follows:
performing chromatography on silica gel column with CHCl3MeOH as elutionGradient elution is carried out on the system, and active compounds are obtained by fractional collection, namely the visible light serum extract.
Further, the process of extracting the cassia seed extract is as follows:
drying and pulverizing semen Cassiae, wetting with 15% sulfuric acid solution for 5d, reflux-extracting with chloroform for 3h, cooling slightly, vacuum-filtering, separating acid water layer from extractive solution, and repeatedly washing with distilled water to obtain chloroform extractive solution;
repeatedly extracting the chloroform extract with a buffer solution with a pH of 8.0 to obtain a raffinate phase, and repeatedly extracting the raffinate phase with a 0.2% NaOH solution;
mixing NaOH extraction liquid, dropwise adding hydrochloric acid under the stirring condition until the pH value of the system is 3, performing suction filtration after complete precipitation, washing the precipitate to be neutral by using distilled water, and drying;
dissolving the precipitate with acetone, performing chromatography with silica gel column, eluting with petroleum ether-ethyl acetate, collecting yellow color band, mixing the fractions, concentrating, standing for crystallization, collecting crystal, repeating column chromatography for separation, and recrystallizing with acetone to obtain semen Cassiae extract.
Further, the extraction process of the hawthorn extract and the medlar extract is as follows:
soaking fructus crataegi or fructus Lycii in distilled water for 30min, heating to boil, slightly boiling for 60min, press filtering, decocting fructus crataegi or fructus Lycii in distilled water for 30min, mixing decoctions, vacuum concentrating, and slowly concentrating in 50 deg.C water bath to obtain fructus crataegi extract or fructus Lycii extract.
The traditional Chinese medicine composition comprises the following raw materials in percentage by mass: see serum 1000: 100-2000 parts of cassia seed: 10-1000 parts of hawthorn: 5-500 of medlar.
An oral preparation containing the Chinese medicinal composition is a tablet or a capsule.
Further, the feed additive is prepared from the following substances in percentage by mass: 10 of the traditional Chinese medicine composition: dextrin 3: sodium carboxymethylcellulose 1: sodium hydroxypropyl cellulose 2: and 0.2 of magnesium stearate.
Further, the oral preparation is a capsule and is prepared from the following substances in percentage by mass: 10 of the traditional Chinese medicine composition: dextrin 5: sodium carboxymethylcellulose 1: and 0.2 of magnesium stearate.
The invention has the beneficial effects that: the embodiment of the invention adopts the serum and the extracts of the cassia seed, the medlar and the hawthorn, and the processed extract is tabletted or prepared into capsules, can be used for treating hypertension and hyperlipidemia, can treat both symptoms and root causes, and has the advantages of quick response, short treatment course and small toxic and side effects.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only some embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to the drawings without creative efforts.
FIG. 1 is a graph showing the effect of Chinese medicinal composition 1 on pancreatic lipase activity.
FIG. 2 is a graph showing the effect of oleic acid on HepG2 cells.
FIG. 3 is a graph showing the effect of a Chinese medicinal composition on the synthesis of triglyceride.
FIG. 4 is a graph showing the effect of a Chinese medicinal composition on lipid synthesis.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The traditional Chinese medicine composition for reducing blood pressure and blood fat in the application comprises the following raw materials in percentage by mass: see serum 1000: 100-2000 parts of cassia seed: 10-1000 parts of hawthorn: 5-500 parts of medlar, and the mass of each raw material is calculated according to raw materials.
Example 1
The preparation process of the traditional Chinese medicine composition is as follows:
dispersing the extract by using a proper amount of water, adding ethanol until the volume concentration of the extract is 80-90%, uniformly stirring, precipitating for 24h, filtering, recovering ethanol from the filtrate, extracting the filtered ethanol extract by using chloroform and ethyl acetate respectively, and separating and purifying the extracted components to obtain a series of extracts;
the specific separation and purification process is as follows:
the chloroform fraction was chromatographed on silica gel using CHCl3Performing gradient elution with MeOH as elution system, and collecting active compound Liparis alkaloid (total alkaloids) in parts, including extract 1, extract 2 and extract 3;
the ethyl acetate fraction was chromatographed on silica gel column using CHCl3Performing gradient elution with/MeOH as elution system, and collecting fractions to obtain active compounds Phenolic glycosides (Phenolic glycoside), including extract 4, extract 5 and extract 6;
respectively vacuum concentrating active compound Liparis alkaloid and active compound Phenolic glycosides to dry, and dispersing with small amount of pure water to obtain extract I and extract II.
and 3, mixing and compounding the extract I, the semen cassiae extract, the hawthorn extract and the medlar extract to obtain a traditional Chinese medicine composition 1, and mixing and compounding the extract II, the semen cassiae extract, the hawthorn extract and the medlar extract to obtain a traditional Chinese medicine composition 2.
When the extraction time in the step 1 is short, the effective substances in the serum are not completely dissolved out, the yield of the extract is low, serum resources are wasted, when the extraction time is long, the dissolution of the effective substances is balanced, the labor and material costs are only increased after the time is prolonged, the impurity leaching amount in the extract is increased, and the extraction effect is reduced.
Meanwhile, the polar solution is not beneficial to the dissolution of effective substances when the extraction temperature is low, and the effective components in the serum can be damaged when the extraction temperature is high, so that the quality of the serum extract is influenced.
When ethanol is used for extraction in the step 1, the volume concentration of the ethanol is too low, so that the aim of removing most of insoluble impurities of the alcohol cannot be achieved, and the use amount of the ethanol is increased due to too high volume concentration, so that waste is caused; the precipitation time is too short, so that the impurities in the serum are not fully precipitated, the impurities are not completely removed, the time is too long, and equipment and manpower are wasted.
The extraction process of the cassia seed extract is as follows:
drying and powdering semen cassiae, weighing 200g of semen cassiae, placing the semen cassiae into a 1000-20000 mL round bottom flask or an extraction tank, adding 200-4000 mL of sulfuric acid solution with volume concentration of 15% for wetting for 5d, then adding 500-10000 mL of chloroform for reflux extraction for 3h, slightly cooling, performing suction filtration, discarding residues, transferring chloroform extract into a separating funnel/knockout, and repeatedly washing the chloroform extract for 3 times by using 75-1500 mL of distilled water after an acid-water layer is separated out to obtain chloroform extract.
Putting the chloroform extracting solution into a 100-20000 mL separating funnel/knockout, repeatedly extracting 5 times by using 150-3000 mL buffer solution with the pH value of 8.0 to obtain raffinate, putting the raffinate into a 1000-20000 mL separating funnel/knockout, and repeatedly extracting 4 times by using 200-4000 mL NaOH with the volume concentration of 0.2%.
And mixing the sodium hydroxide extract, placing the mixed sodium hydroxide extract in a beaker/reaction kettle with the volume of 1000-20000 mL, dropwise adding hydrochloric acid under stirring until the pH value is 3.0, after complete precipitation, performing suction filtration, washing the precipitate with a small amount of distilled water to be neutral, and naturally drying the precipitate for later use.
Weighing 1g of precipitate, putting the precipitate in an evaporation dish, adding an appropriate amount of acetone for dissolving, adding 25g of silica gel for column chromatography, stirring uniformly, and volatilizing in a fume hood for later use.
Weighing 200G of silica gel, adding petroleum ether-ethyl acetate (28: 1), uniformly stirring, placing into a chromatographic column, performing dry-method sampling, eluting with petroleum ether-ethyl acetate, collecting yellow color bands, each 20mL, checking each fraction with a silica gel G plate, combining the fractions, slightly concentrating, standing for crystallization, collecting crystals, repeating column chromatography separation once again, and recrystallizing with analytically pure acetone to obtain the cassia seed extract.
The preparation process of the hawthorn extract comprises the following steps:
placing 100g of fructus crataegi in a beaker, adding appropriate amount of distilled water, soaking for 30min, heating to boil, keeping slightly boiling for 60min, press filtering, adding 5 times of distilled water into the residue, decocting for 30min, mixing decoctions, vacuum concentrating, slowly evaporating in 50 deg.C water bath, concentrating to obtain fructus crataegi extract, and storing in 4 deg.C refrigerator.
The preparation process of the medlar extract comprises the following steps:
placing 50g of fructus Lycii in a beaker, adding appropriate amount of distilled water to immerse the medicinal materials, soaking for 30min, heating to boil, keeping slightly boiling for 60min, filtering, adding distilled water 4 times the mass of the medicinal residues, decocting for 30min again according to the method, mixing the decoctions for 2 times, vacuum concentrating, slowly evaporating and concentrating in a 50 deg.C water bath kettle to obtain fructus Lycii extract, and storing in a 4 deg.C refrigerator for use.
Example 2
The preparation process of the traditional Chinese medicine composition in the embodiment 1 is used for preparing the traditional Chinese medicine composition, and the raw materials are as follows by mass: see serum 1000: 100 of cassia seed: 10 of hawthorn fruit: and 5, the medlar 5, wherein the extract of the Chinese medicinal composition for treating the phlegmonous disease is total alkaloid separated from a chloroform part.
Example 3
The preparation process of the traditional Chinese medicine composition in the embodiment 1 is used for preparing the traditional Chinese medicine composition, and the raw materials are as follows by mass: see serum 1000: 400 parts of cassia seed: 200 of hawthorn fruit: 100 parts of medlar, wherein the extract of the Chinese medicinal composition for treating the acute coronary heart disease is total alkaloid separated from chloroform parts.
Example 4
The preparation process of the traditional Chinese medicine composition in the embodiment 1 is used for preparing the traditional Chinese medicine composition, and the raw materials are as follows by mass: see serum 1000: 800 parts of cassia seed: 400 of hawthorn fruit: 200 parts of medlar, wherein the extract of the Chinese medicinal composition for treating the acute coronary heart disease is total alkaloid separated from chloroform parts.
Example 5
The preparation process of the traditional Chinese medicine composition in the embodiment 1 is used for preparing the traditional Chinese medicine composition, and the raw materials are as follows by mass: see serum 1000: cassia seed 1200: the hawthorn fruit is 600: 300 of medlar, wherein the extract of the Chinese medicinal composition for treating the acute coronary heart disease is total alkaloid separated from chloroform parts.
Example 6
The preparation process of the traditional Chinese medicine composition in the embodiment 1 is used for preparing the traditional Chinese medicine composition, and the raw materials are as follows by mass: see serum 1000: 1600 parts of cassia seed: 800 parts of hawthorn fruit: the medlar 400 and the sanguisorba extract in the traditional Chinese medicine composition are total alkaloids obtained by separating chloroform parts.
Example 7
The preparation process of the traditional Chinese medicine composition in the embodiment 1 is used for preparing the traditional Chinese medicine composition, and the raw materials are as follows by mass: see serum 1000: cassia seed 2000: 1000 parts of hawthorn fruit: the medlar 500 and the sanguinarine extract in the traditional Chinese medicine composition are total alkaloids obtained by separating chloroform parts.
Example 8
Selecting 80 mice for experiment, and dividing 10 mice into eight groups, wherein two groups are blank groups, three groups are serum extract experimental groups, three groups are traditional Chinese medicine composition 1 (prepared in example 1) experimental groups, and the serum extract experimental groups and the traditional Chinese medicine composition 1 experimental groups are respectively divided into a low-dose group, a medium-dose group and a high-dose group;
first, adaptive feeding is performed
The mice are fed for 3-5 days in an environmental adaptability manner in a standard laboratory environment, then weighed, blood at the tail tips of the mice is taken, serum is obtained by centrifugation, and the Triglyceride (TG) content, the low-density lipoprotein cholesterol (LDLC) content and the high-density lipoprotein cholesterol (HDLC) content of the mice are measured by using a full-automatic biochemical analyzer.
Second, experiment
Wherein the blank group 1 is fed with basic feed and drinking water, and is perfused with normal saline, and the dosage of the normal saline is 0.3mL/10g according to the mass of the mouse.
The blank group 2 is fed with high-fat feed and drinking water, wherein the high-fat feed is prepared by mixing the following substances in percentage by mass: 75% of basal feed, 15% of protein powder and 10% of lard, and the stomach is irrigated with normal saline, wherein the dosage of the normal saline is 0.3mL/10g according to the mass of the mouse.
The serum extract experimental group is fed by using high-fat feed and drinking water, wherein the high-fat feed is prepared by mixing the following substances in percentage by mass: 75% of basal feed, 15% of protein powder and 10% of lard, and the stomach is drenched by using a serum extract, wherein the dosage of the serum extract is 0.3mL/10g according to the mass of a mouse; wherein the concentration of the serum extract used in the low dose group was 20. mu.g/mL, the concentration of the serum extract used in the medium dose group was 50. mu.g/mL, and the concentration of the serum extract used in the high dose group was 100. mu.g/mL, wherein the serum extract was the extract prepared in example 1 without separation and purification.
The traditional Chinese medicine composition 1 is fed by high-fat feed and drinking water in experimental groups, and the high-fat feed is prepared by mixing the following substances in percentage by mass: 75% of basal feed, 15% of protein powder and 10% of lard, and the stomach is irrigated by using a traditional Chinese medicine composition 1, wherein the dosage of the traditional Chinese medicine composition 1 is 0.3mL/10g according to the mass of a mouse; wherein the concentration of the traditional Chinese medicine composition 1 used in the low-dose group is 20 mug/mL, the concentration of the traditional Chinese medicine composition 1 used in the medium-dose group is 50 mug/mL, and the concentration of the traditional Chinese medicine composition 1 used in the high-dose group is 100 mug/mL.
Feeding for 28 days according to the above method, weighing once every 3 days, stopping water and fasting one day before experiment, weighing 2h after the last administration, taking blood from heart, centrifuging to obtain serum, and determining Triglyceride (TG) content, Low Density Lipoprotein Cholesterol (LDLC) content and High Density Lipoprotein Cholesterol (HDLC) content of mouse by using full-automatic biochemical analyzer.
According to the blank groups 1 and 2, the blood pressure and the blood fat of the mice fed with the high-fat feed are obviously improved, after the mice are treated by the serum extract, the blood pressure and the blood fat of the mice are reduced to a certain extent, but the effect is not obvious, and the mice have symptoms such as appetite reduction, weight reduction, diarrhea and the like, and the blood pressure and blood fat reducing effects are improved a little along with the increase of the concentration of the serum extract, but the side effect is more obvious; after the traditional Chinese medicine composition 1 is used for treating the mice, the blood pressure and the blood fat of the mice are obviously reduced, the action effect is in direct proportion to the concentration of the traditional Chinese medicine composition 1, and the individual mice have the symptoms of appetite reduction, but have little influence on the weight and have no diarrhea.
Example 9
1. Measurement of blood lipid-lowering Activity
The blood fat reducing activity of the traditional Chinese medicine composition is determined by measuring the content of triglyceride and cholesterol in HepG2 cells in vitro.
(1) Cell culture
HepG2 cells were plated in high-glucose DMEM medium at 37 ℃ with 5% CO2The culture medium of (4) was cultured in a high-glucose DMEM medium containing 10% fetal bovine serum, 100. mu.g/mL penicillin and 100. mu.g/mL streptomycin.
(2) Experiment on influence of the traditional Chinese medicine composition 1 and the traditional Chinese medicine composition 2 prepared in example 1 on HepG2 cell viability
HepG2 cells were first pretreated:
HepG2 cells were trypsinized and then treated at 3X 105Inoculating each well into 96-well plate, incubating at 37 deg.C for 24 hr, removing cell supernatant after incubation, and further incubating at 37 deg.C for 24 hr with growth medium containing Chinese medicinal composition 1, Chinese medicinal composition 2, and oleic acid with different molar concentrations.
The mass concentrations of the traditional Chinese medicine composition 1 and the traditional Chinese medicine composition 2 are respectively 0, 10 mu g/mL, 50 mu g/mL, 100 mu g/mL, 200 mu g/mL and 500 mu g/mL, and the molar concentrations of the oleic acid are respectively 0.125mmol/L, 0.25mmol/L, 0.5mmol/L, 1.0mmol/L and 2.0 mmol/L.
And (3) activity determination: taking HepG2 cells treated by traditional Chinese medicine composition 1, traditional Chinese medicine composition 2 or oleic acid, removing cell supernatant, injecting 100. mu.L of thiazole blue solution with mass concentration of 0.05g/mL into each hole, continuing incubation at 37 ℃ for 30min, then washing HepG2 cells twice by PBS, adding 100. mu.L of dimethyl sulfoxide into each hole to dissolve formazan in the cells, and measuring the optical density value of the dimethyl sulfoxide solution at a wavelength of 50nm after shaking for 20 min.
The control group is prepared by adding no Chinese medicinal composition and oleic acid, and dimethyl sulfoxide is used as solvent blank.
The experimental results are as follows: as shown in figure 1, within the mass concentration range of 0-500 mug/mL, the traditional Chinese medicine composition 1 and the traditional Chinese medicine composition 2 have different degrees of inhibition effects on pancreatic lipase activity, wherein the traditional Chinese medicine composition 1 has stronger inhibition effect on pancreatic lipase activity, and the inhibition effect is obviously improved along with the increase of the mass concentration.
As shown in FIG. 2, after HepG2 cells are treated by the growth medium containing oleic acid, the growth medium has obvious inhibition effect on the activity of the HepG2 cells, and has larger toxicity on the HepG2 cells when the concentration of the oleic acid is too high, and the cells are cultured optimally when the molar concentration of the oleic acid is 0.125-0.5 mmol/L.
(3) Experiment on influence of the traditional Chinese medicine composition 1 and the traditional Chinese medicine composition 2 prepared in example 1 on synthesis of high-fat HepG2 cell model triglyceride
Dissolving Chinese medicinal composition 1 or 2 in a molar concentration of 10-2M in DMSO, diluted to 10-5M, taking HepG2 cells at 3X 105Inoculating each cell to a 96-well plate, after the cells are attached to the wall, washing the HepG2 cells by using a DMEM culture medium without the traditional Chinese medicine composition, incubating the cells for 12 hours at 37 ℃ by using a DMEM culture medium containing different mass concentrations (0, 10 mu g/mL, 50 mu g/mL, 100 mu g/mL, 200 mu g/mL and 500 mu g/mL) of the traditional Chinese medicine composition 1 or the traditional Chinese medicine composition 2, then removing cell supernatant, continuously culturing the cells for 24 hours by using an induction culture medium containing oleic acid, and culturing the normal HepG2 cells for 36 hours by using the DMEM culture medium as a blank group.
After the incubation is finished, the cells are gently washed by PBS for 3 times, then the cells are lysed by RIPA lysate in ice bath for 30min, then the cells are centrifuged for 15min at 4 ℃ and 10000rpm, supernatant is taken, the cell protein content is determined by a BCA protein detection kit, the triglyceride content in the supernatant is determined by a triglyceride detection kit, and the result is calculated by the protein mass.
The experimental results are as follows: as shown in fig. 3, compared with the blank group control results, the contents of triglyceride in the oleic acid-induced high-fat HepG2 cell model were decreased after treatment with the traditional Chinese medicine composition 1 and the traditional Chinese medicine composition 2, which indicates that the traditional Chinese medicine composition 1 and the traditional Chinese medicine composition 2 both have an inhibitory effect on the synthesis of triglyceride in the high-fat HepG2 cells, wherein the inhibitory activity of the traditional Chinese medicine composition 1 on the synthesis of triglyceride in the high-fat HepG2 cells is strongest.
(4) Experiment on the Effect of the Chinese medicinal composition 1 prepared in example 1 on lipid Synthesis in the high cholesterol HepG2 cell model
Dissolving Chinese medicinal composition 1 in a molar concentration of 10-2M in DMSO, diluted to 10-5M, the DMSO is used as a solvent to facilitate the penetration of the Chinese medicinal composition 1, and is also a penetration protective agent, HepG2 cells are taken to be 3 × 105Inoculating each well to a 96-well plate, allowing the plate to adhere, removing cell supernatant, incubating for 12h at 37 ℃ in DMEM containing traditional Chinese medicine composition 1 with different mass concentrations (0, 10 mu g/mL, 50 mu g/mL, 100 mu g/mL, 200 mu g/mL, 500 mu g/mL), removing cell supernatant, further culturing for 24h in an induction culture medium containing cholesterol, culturing for 12h in DMEM, removing cell supernatant, and further culturing for 24h in a culture medium containing 15mg/mL cholesterol and 0.2mg/mL simvastatin to obtain a simvastatin positive control group.
After the incubation is finished, the cells are gently washed by PBS for 3 times, the cells are lysed by RIPA lysate in ice bath for 30min, the cells are centrifuged for 15min at 4 ℃ and 10000rpm, the supernatant is taken, the cell protein content is measured by a BCA protein detection kit, the total cholesterol content in HepG2 cells is measured by a total cholesterol detection kit, and the result is measured by the protein mass.
The experimental results are as follows: according to the experiment results, the traditional Chinese medicine composition 1 with the strongest inhibition effect on the triglyceride of the high-fat HepG2 cell model is selected to perform an influence experiment on lipid synthesis in the high-cholesterol HepG2 cell model, as shown in fig. 4, compared with a blank control, 0.2mg/mL of simvastatin and the traditional Chinese medicine composition 1 can obviously reduce the content of total cholesterol in the HepG2 cell model, which shows that the simvastatin and the traditional Chinese medicine composition 1 can effectively inhibit the lipid synthesis in the high-cholesterol HepG2 cell model, the inhibition activity of the simvastatin and the traditional Chinese medicine composition 1 on the lipid synthesis in the high-cholesterol HepG2 cell model is gradually increased along with the increase of the concentration of the traditional Chinese medicine composition 1, and the inhibition effect is the best when the mass concentration of the simvastatin and the traditional Chinese medicine composition is 500 mug/mL.
(5) Experiment on Effect of the Chinese medicinal compositions prepared in examples 2 to 7 on HepG2 cell viability
HepG2 cell channelAfter trypsinization, the mixture was digested at 3X 105Inoculating each well into a 96-well plate, incubating at 37 ℃ for 24h, removing cell supernatant after incubation, and further incubating at 37 ℃ for 24h by using growth culture media containing the traditional Chinese medicine compositions prepared in examples 2-7 respectively, wherein the traditional Chinese medicine compositions prepared in each example are provided with 5 experimental groups, and the mass concentrations of the traditional Chinese medicine compositions are respectively 0, 10 [ mu ] g/mL, 50 [ mu ] g/mL, 100 [ mu ] g/mL, 200 [ mu ] g/mL and 500 [ mu ] g/mL;
and (3) activity determination: taking HepG2 cells treated by the traditional Chinese medicine composition, removing cell supernatant, injecting 100 μ L of thiazole blue solution with the mass concentration of 0.05g/mL into each hole, continuing to incubate at 37 ℃ for 30min, then washing the HepG2 cells twice by PBS, adding 100 μ L of dimethyl sulfoxide into each hole to dissolve formazan in the cells, and measuring the optical density value of the dimethyl sulfoxide solution at the wavelength of 50nm after shaking for 20min to obtain the inhibition data of the traditional Chinese medicine composition on the pancreatic lipase activity in each experimental group, wherein the inhibition data are shown in Table 1:
TABLE 1 inhibition data of pancreatic lipase activity by Chinese medicinal composition
Example 10
Weighing 1100 g of the traditional Chinese medicine composition, 50g of dextrin, 10g of sodium carboxymethylcellulose and 2g of magnesium stearate, uniformly mixing the materials, sieving the mixture by a 80-mesh sieve, granulating the mixture by using a dry granulator, and filling the granules into capsules after granulating the granules by using a 60-mesh sieve to prepare the traditional Chinese medicine composition capsules, wherein the dextrin is used as an excipient and a filler, the sodium carboxymethylcellulose is used as a thickening agent, and the magnesium stearate is used as a glidant.
Example 11
1100 g of the traditional Chinese medicine composition, 30g of dextrin, 10g of sodium carboxymethylcellulose, 20g of sodium hydroxypropylcellulose and 2g of magnesium stearate are weighed, the materials are uniformly mixed and sieved by a 80-mesh sieve, a dry granulator is used for granulation, and a 60-mesh sieve is used for size stabilization, tabletting and coating to obtain the traditional Chinese medicine composition tablet, wherein the dextrin is used as an excipient and a filler, the sodium carboxymethylcellulose is used as a thickening agent, the sodium hydroxypropylcellulose is used as a film coating material and an adhesive of the tablet, and the magnesium stearate is used as a glidant in tabletting.
100 volunteers are divided into three groups, the first 40 volunteers take the Chinese medicinal composition tablet prepared in the embodiment 11, three times a day, 2-4 tablets each time, the 41 st to 80 th volunteers take the Chinese medicinal composition capsule prepared in the embodiment 10, 2-4 capsules each time, the 81 st to 100 th volunteers take 1100 g of the Chinese medicinal composition prepared in the embodiment 1, three times a day, 2-4 parts each time, and the treatment and observation are carried out continuously for one year, the experimental groups and the effectiveness parameters are shown in table 2, wherein 88 cases with obvious effects and 12 cases with obvious effects are obtained, the symptoms of hypertension and hyperlipidemia of all volunteers are well relieved, the blood fat data of patients before and after taking the medicine are shown in table 3, no obvious toxic or side effect is found in the patients, the patients with extremely small stomach cold have slight diarrhea, the patients can eat warm medicine and food such as Chinese dates, and the correction of taking the Chinese medicinal composition 1 and the tablets prepared from the Chinese medicinal composition 1 in the embodiment can be known from table 3, The capsule can effectively reduce the blood pressure and the blood fat of patients, and has mild action process and less side effect.
Table 2 experimental grouping and validity parameters
| Group of | Example number (human) | Display effect (human) | Effective (human) | Total |
| 1 | 40 | 36 | 4 | 100％ |
| 2 | 40 | 32 | 8 | 100％ |
| 3 | 20 | 18 | 2 | 100％ |
TABLE 3 blood pressure and blood lipid values of volunteers before and after the experiment
The serum belongs to cold Chinese herbal medicines, has complex chemical components, can be directly used for reducing blood pressure and blood fat without separation and purification, can cause stimulation to gastrointestinal tracts, particularly people with weaker gastrointestinal function can have symptoms such as nausea and vomiting in severe cases, can also cause appetite reduction and diarrhea, has insignificant effects of reducing blood pressure and blood fat, and has slow effect, the embodiment obtains the effective component-total alkaloids in the serum by separation and purification through the method, extracts anthraquinone components in the cassia seeds, including chrysophanol, physcion, obtusin, aurantiol, lycium barbarum and the like, is supplemented with full-component extracts of hawthorn and medlar, is compounded to obtain the traditional Chinese medicine composition, the cassia seeds have the laxative effect, the hawthorn extract contains rich fruit acids and organic acids, can stimulate the secretion of digestive juice, improve the spleen and stomach functions of human bodies, relieve the symptoms such as diarrhea and inappetence, the fructus Lycii extract has effects of nourishing yin, invigorating kidney, and tranquilizing mind, and also has effects of regulating blood sugar in two directions due to its fructus Lycii polysaccharide; in conclusion, the effects of the substances in the traditional Chinese medicine composition provided by the embodiment supplement each other, the effect of reducing blood fat and blood pressure is realized in a short time, and side effects caused by ineffective components, irritant components and the like are avoided.
All the embodiments in the present specification are described in a related manner, and the same and similar parts among the embodiments may be referred to each other, and each embodiment focuses on the differences from the other embodiments. In particular, for the system embodiment, since it is substantially similar to the method embodiment, the description is simple, and for the relevant points, reference may be made to the partial description of the method embodiment.
The above description is only for the preferred embodiment of the present invention, and is not intended to limit the scope of the present invention. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention shall fall within the protection scope of the present invention.
Claims (9)
1. The preparation method of the traditional Chinese medicine composition is characterized by comprising the following steps:
step 1, cleaning dried serum, removing impurities, sieving, repeatedly extracting with an acidic polar solution, combining extracting solutions, neutralizing with a dilute alkali solution to make the pH value of the system be 6.5-7.5, and recovering a polar solvent in vacuum to obtain an extract;
step 2, dispersing the extract with water, adding ethanol for precipitation for 24 hours, filtering, recovering ethanol from filtrate, extracting the ethanol extract with chloroform, and separating and purifying the extracted components to obtain a serum extract;
and 3, respectively extracting the cassia seed extract, the hawthorn extract and the medlar extract, and mixing the serum extract and the extracts to obtain the traditional Chinese medicine composition.
2. The method for preparing a Chinese medicinal composition according to claim 1, wherein the specific process of repeatedly extracting in step 1 is as follows:
extracting for 1-10 h at 25-90 ℃ by using an acidic polar solvent, and extracting for 0.5-1.5 h at 25-90 ℃ by using an acidic polar solvent, wherein the pH value of the acidic polar solvent is 1.0-3.0.
3. The method for preparing a Chinese medicinal composition according to claim 1, wherein the separation and purification process in step 2 is as follows:
performing chromatography on silica gel column using CHCl3Performing gradient elution with/MeOH as elution system, and collecting active compounds by parts to obtain the product, i.e. the extract of the blood serum.
4. The method for preparing a Chinese medicinal composition according to claim 1, wherein the process for extracting the cassia seed extract comprises the following steps:
drying and pulverizing semen Cassiae, wetting with 15% sulfuric acid solution for 5d, reflux-extracting with chloroform for 3h, cooling slightly, vacuum-filtering, separating acid water layer from extractive solution, and repeatedly washing with distilled water to obtain chloroform extractive solution;
repeatedly extracting the chloroform extract with a buffer solution with a pH of 8.0 to obtain a raffinate phase, and repeatedly extracting the raffinate phase with a 0.2% NaOH solution;
mixing NaOH extraction liquid, dropwise adding hydrochloric acid under the stirring condition until the pH value of the system is 3, performing suction filtration after complete precipitation, washing the precipitate to be neutral by using distilled water, and drying;
dissolving the precipitate with acetone, performing chromatography with silica gel column, eluting with petroleum ether-ethyl acetate, collecting yellow color band, mixing the fractions, concentrating, standing for crystallization, collecting crystal, repeating column chromatography for separation, and recrystallizing with acetone to obtain semen Cassiae extract.
5. The method for preparing a Chinese medicinal composition according to claim 1, wherein the extraction process of the hawthorn extract and the medlar extract is as follows:
soaking fructus crataegi or fructus Lycii in distilled water for 30min, heating to boil, slightly boiling for 60min, press filtering, decocting fructus crataegi or fructus Lycii in distilled water for 30min, mixing decoctions, vacuum concentrating, and slowly concentrating in 50 deg.C water bath to obtain fructus crataegi extract or fructus Lycii extract.
6. The traditional Chinese medicine composition prepared by the preparation method of the traditional Chinese medicine composition according to any one of claims 1 to 5, which is characterized in that the mass ratio of the raw materials based on raw materials is as follows: see serum 1000: 100-2000 parts of cassia seed: 10-1000 parts of hawthorn: 5-500 of medlar.
7. An oral preparation made from the Chinese medicinal composition of claim 6, wherein the oral preparation is a tablet or a capsule.
8. The traditional Chinese medicine composition oral preparation according to claim 7, wherein the oral preparation is a tablet and is prepared from the following substances in parts by mass: 10 of the traditional Chinese medicine composition: dextrin 3: sodium carboxymethylcellulose 1: sodium hydroxypropyl cellulose 2: and 0.2 of magnesium stearate.
9. The traditional Chinese medicine composition oral preparation according to claim 7, wherein the oral preparation is a capsule prepared from the following substances in parts by mass: 10 of the traditional Chinese medicine composition: dextrin 5: sodium carboxymethylcellulose 1: and 0.2 of magnesium stearate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210250536.3A CN114470101A (en) | 2022-03-15 | 2022-03-15 | Traditional Chinese medicine composition, preparation method thereof and oral agent containing traditional Chinese medicine composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210250536.3A CN114470101A (en) | 2022-03-15 | 2022-03-15 | Traditional Chinese medicine composition, preparation method thereof and oral agent containing traditional Chinese medicine composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114470101A true CN114470101A (en) | 2022-05-13 |
Family
ID=81486899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210250536.3A Pending CN114470101A (en) | 2022-03-15 | 2022-03-15 | Traditional Chinese medicine composition, preparation method thereof and oral agent containing traditional Chinese medicine composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114470101A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115671203A (en) * | 2022-11-24 | 2023-02-03 | 广州中医药大学科技产业园有限公司 | Traditional Chinese medicine compound extract for reducing blood sugar and blood fat and extraction method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1739599A (en) * | 2005-09-12 | 2006-03-01 | 周然 | Blood fat reducing and liver protecting medicine prepared with cassia seed extract |
| CN102274403A (en) * | 2011-08-09 | 2011-12-14 | 南京泽朗医药科技有限公司 | Method for extracting total alkaloids from liparis nervosa |
| CN104893926A (en) * | 2015-06-29 | 2015-09-09 | 铜川市药师佛养生酒业有限公司 | Well-being healthcare medicated wine and preparation method thereof |
-
2022
- 2022-03-15 CN CN202210250536.3A patent/CN114470101A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1739599A (en) * | 2005-09-12 | 2006-03-01 | 周然 | Blood fat reducing and liver protecting medicine prepared with cassia seed extract |
| CN102274403A (en) * | 2011-08-09 | 2011-12-14 | 南京泽朗医药科技有限公司 | Method for extracting total alkaloids from liparis nervosa |
| CN104893926A (en) * | 2015-06-29 | 2015-09-09 | 铜川市药师佛养生酒业有限公司 | Well-being healthcare medicated wine and preparation method thereof |
Non-Patent Citations (5)
| Title |
|---|
| 张仁强 等: "草药见血清中化学物质的提取及医用功效探讨", 《教育教学论坛》 * |
| 张晓路 等: "决明子中总蒽醌苷元的大孔吸附树脂纯化工艺的研究", 《中草药》 * |
| 徐岩 等: "中西医结合治疗高脂血症疗效观察", 《辽宁中医杂志》 * |
| 朱彩燕: "决明子中大黄素的提取、分离和纯化方法的研究", 《中国现代药物应用》 * |
| 李国平 等: "见血清总生物碱提取工艺的优化", 《武夷学院学报》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115671203A (en) * | 2022-11-24 | 2023-02-03 | 广州中医药大学科技产业园有限公司 | Traditional Chinese medicine compound extract for reducing blood sugar and blood fat and extraction method thereof |
| CN115671203B (en) * | 2022-11-24 | 2023-10-27 | 广州中医药大学科技产业园有限公司 | A Chinese medicinal compound extract for lowering blood sugar and blood lipid, and its extraction method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2349337C2 (en) | Pharmaceutical composition including steroid saponins, method of obtainment, and application | |
| CN103127192A (en) | Preparation method for fresh ginseng extractive and application thereof in II-type diabetics | |
| CN111117773B (en) | Method for separating nervonic acid from garlic oil and application thereof | |
| CN107118219B (en) | The method of separating-purifying gelsevirine, koumidine, koumine, gelsemine and furans koumine from elegant jessamine | |
| CN101357192B (en) | Separation preparation method of gastrodia elata crude polysaccharide and gastrodia elata alcohol extract using fresh gastrodia elata as raw material | |
| CN114470101A (en) | Traditional Chinese medicine composition, preparation method thereof and oral agent containing traditional Chinese medicine composition | |
| CN108339000B (en) | Panax plant extract, and pharmaceutical composition and application thereof | |
| CN112159451A (en) | Gynostemma pentaphylla saponin extract and preparation method thereof | |
| CN115010618B (en) | Separation and purification method of aureoyl amide alcohol ester capable of reducing uric acid and application thereof | |
| CN109602759B (en) | Application of podocarpus macrophyllus polysaccharide | |
| CN108524668B (en) | Preparation method of Chinese wolfberry extract with repairing and treating effects on drug-induced liver injury | |
| CN113429452B (en) | Acylated mogroside derivatives as anti-inflammatory agents and anti-inflammatory compositions | |
| CN109674848A (en) | A kind of preparation method and purposes of licorice | |
| CN110960569A (en) | Phyllanthus emblica extract and preparation method and application thereof | |
| CN109467581B (en) | Method for extracting flavonoid glycoside from lotus leaves and pharmaceutical preparation containing flavonoid glycoside from lotus leaves | |
| CN101371875B (en) | Method for extracting and preparing total saponin of compound abnormal savda mature agent | |
| CN111253459B (en) | A notoginsenoside processed product and its preparation method and application | |
| CN111150811A (en) | Formula of blood sugar reducing powder | |
| CN115708553B (en) | Naringin-containing composition and application thereof in preparation of naringin-containing beverage | |
| CN107261002B (en) | Traditional Chinese medicine composition for treating hyperlipidemia, preparation method and application thereof | |
| CN112168878B (en) | Radix polygalae fallax hemsl-water lotus lipid-lowering composition and preparation method thereof | |
| KR100391195B1 (en) | a manufacturing technique of a beverage using of an educt which is distilled from Liriope spicata Lour | |
| CN114835662B (en) | Gallate novel compound in myrobalan and preparation method and application thereof | |
| CN112794812B (en) | Alkaloid compound extracted from banana flower and extraction method thereof | |
| CN102406673A (en) | Chinese eupatorium root ketoside medicine for preparing and curing respiratory tract infection and urinary tract infection and preparations and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220513 |